{"url_path":"/sec/okyo/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1849296/0001493152-26-033847-index.html","accession_number":"0001493152-26-033847","cik":"0001849296","ticker":"OKYO","issuer_name":"OKYO Pharma Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1849296/0001493152-26-033847-index.html","primary_entity_key":"0001849296","primary_entity_name":"OKYO Pharma Ltd"},"word_count":1466,"has_tables":true,"body_markdown":"false\nFY\n0001849296\n\n0001849296\n\n2025-04-01\n2026-03-31\n\n0001849296\n\ndei:BusinessContactMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\n2026-07-15\n\n0001849296\n\n2026-03-31\n\n0001849296\n\n2025-03-31\n\n0001849296\n\n2024-04-01\n2025-03-31\n\n0001849296\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2023-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2023-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2023-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2023-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2023-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2023-03-31\n\n0001849296\n\n2023-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2024-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2024-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2024-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2024-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2024-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2024-03-31\n\n0001849296\n\n2024-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2025-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2025-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2025-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2025-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2025-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2025-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2026-03-31\n\n0001849296\n\nifrs-full:OtherReservesMember\n\n2026-03-31\n\n0001849296\n\nOKYO:WarrantReservesMember\n\n2026-03-31\n\n0001849296\n\nOKYO:ConvertibleLoanNoteReserveMember\n\n2026-03-31\n\n0001849296\n\nifrs-full:RetainedEarningsMember\n\n2026-03-31\n\n0001849296\n\nOKYO:TranslationReserveMember\n\n2026-03-31\n\n0001849296\n\n2018-12-31\n\n0001849296\n\n2026-02-01\n2026-02-28\n\n0001849296\n\nifrs-full:ComputerEquipmentMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:ResearchAndDevelopmentMember\n\n2026-03-31\n\n0001849296\n\nOKYO:ResearchAndDevelopmentMember\n\n2025-03-31\n\n0001849296\n\nOKYO:ResearchAndDevelopmentMember\n\n2024-03-31\n\n0001849296\n\nOKYO:CorporateAndAdministrationMember\n\n2026-03-31\n\n0001849296\n\nOKYO:CorporateAndAdministrationMember\n\n2025-03-31\n\n0001849296\n\nOKYO:CorporateAndAdministrationMember\n\n2024-03-31\n\n0001849296\n\nOKYO:FeeAndShortTermEmployeeBenefitsMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:PostEmploymentBenefitsMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:FeeAndShortTermEmployeeBenefitsMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:PostEmploymentBenefitsMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:FeeAndShortTermEmployeeBenefitsMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:PostEmploymentBenefitsMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:DirectorsMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:DirectorsMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:DirectorsMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:OtherkeymanagementpersonnelMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:OtherkeymanagementpersonnelMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:OtherkeymanagementpersonnelMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:DirectorsAndOtherOfficersMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:DirectorsAndOtherOfficersMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:DirectorsAndOtherOfficersMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:ITEquipmentMember\n\n2025-03-31\n\n0001849296\n\nOKYO:ITEquipmentMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:ITEquipmentMember\n\n2026-03-31\n\n0001849296\n\nOKYO:ITEquipmentMember\n\n2024-03-31\n\n0001849296\n\nOKYO:ITEquipmentMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:UKMember\n\n2026-03-31\n\n0001849296\n\nOKYO:UnitedStateMember\n\n2026-03-31\n\n0001849296\n\nOKYO:UKMember\n\n2025-03-31\n\n0001849296\n\nOKYO:UnitedStateMember\n\n2025-03-31\n\n0001849296\n\nOKYO:IssuedCapitalOrdinarySharesMember\n\n2024-03-31\n\n0001849296\n\nOKYO:IssuedCapitalOrdinarySharesMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:IssuedCapitalOrdinarySharesMember\n\n2025-03-31\n\n0001849296\n\nOKYO:IssuedCapitalOrdinarySharesMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:IssuedCapitalOrdinarySharesMember\n\n2026-03-31\n\n0001849296\n\n2025-01-01\n2025-01-31\n\n0001849296\n\nifrs-full:WarrantReserveMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nifrs-full:WarrantReserveMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:MarchFourteenTwoThousandTwentyThreeMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:MarchFourteenTwoThousandTwentyThreeMember\n\n2026-03-31\n\n0001849296\n\nOKYO:OctoberTwentyTwoThousandTwentyThreeMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:OctoberTwentyTwoThousandTwentyThreeMember\n\n2026-03-31\n\n0001849296\n\nOKYO:NovemberTwentyFourTwoThousandTwentyThreeMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:NovemberTwentyFourTwoThousandTwentyThreeMember\n\n2026-03-31\n\n0001849296\n\nOKYO:MarchOneTwoThousandTwentyFourMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:MarchOneTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001849296\n\nOKYO:MarchThirteenTwoThousandTwentyFourMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:MarchThirteenTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001849296\n\nOKYO:OctoberThreeTwoThousandTwentyFourMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:OctoberThreeTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001849296\n\nOKYO:JanuaryTwentyNineTwoThousandTwentyFiveMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:JanuaryTwentyNineTwoThousandTwentyFiveMember\n\n2026-03-31\n\n0001849296\n\nOKYO:MarchTwentyEightTwoThousandTwentyFiveMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:MarchTwentyEightTwoThousandTwentyFiveMember\n\n2026-03-31\n\n0001849296\n\nOKYO:JulyTenTwoThousandTwentyFiveMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:JulyTenTwoThousandTwentyFiveMember\n\n2026-03-31\n\n0001849296\n\nOKYO:JanuaryTwoTwoThousandTwentySixMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:JanuaryTwoTwoThousandTwentySixMember\n\n2026-03-31\n\n0001849296\n\nOKYO:FebruaryTenTwoThousandTwentySixMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:FebruaryTenTwoThousandTwentySixMember\n\n2026-03-31\n\n0001849296\n\n2026-02-10\n2026-02-10\n\n0001849296\n\nOKYO:GrantOneMember\n\n2026-01-02\n2026-01-02\n\n0001849296\n\nOKYO:GrantTwoMember\n\n2026-01-02\n2026-01-02\n\n0001849296\n\nOKYO:GrantOneMember\n\n2025-07-10\n2025-07-10\n\n0001849296\n\nOKYO:GrantTwoMember\n\n2025-07-10\n2025-07-10\n\n0001849296\n\n2025-03-28\n2025-03-28\n\n0001849296\n\nOKYO:GrantOneMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantTwoMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantThreeMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantFourMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantFiveMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantThreeMember\nifrs-full:BottomOfRangeMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantThreeMember\nifrs-full:TopOfRangeMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantFourMember\nifrs-full:BottomOfRangeMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nOKYO:GrantFourMember\nifrs-full:TopOfRangeMember\n\n2025-01-29\n2025-01-29\n\n0001849296\n\nifrs-full:WarrantReserveMember\n\n2025-03-31\n\n0001849296\n\nifrs-full:WarrantReserveMember\n\n2024-03-31\n\n0001849296\n\nifrs-full:WarrantReserveMember\n\n2026-03-31\n\n0001849296\n\nOKYO:LessThanThreeMember\n\n2026-03-31\n\n0001849296\n\nOKYO:ThreeToTwelveMonthsMember\n\n2026-03-31\n\n0001849296\n\nOKYO:LessThanThreeMember\n\n2025-03-31\n\n0001849296\n\nOKYO:ThreeToTwelveMonthsMember\n\n2025-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:ServiceAgreementMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:ServiceAgreementMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:ServiceAgreementMember\n\n2026-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:ServiceAgreementMember\n\n2025-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\n\n2026-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\n\n2025-03-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:ShorttermCreditFacilityMember\n\n2022-08-01\n2022-08-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:ShorttermCreditFacilityMember\n\n2022-08-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:AdditionalShorttermCreditFacilityMember\n\n2022-08-31\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:AdditionalShorttermCreditFacilityMember\n\n2023-02-01\n2023-02-28\n\n0001849296\n\nOKYO:TizianaLifeSciencesLtdMember\nOKYO:AdditionalShorttermCreditFacilityMember\n\n2023-10-25\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2023-10-25\n2023-10-25\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2024-07-15\n2024-07-15\n\n0001849296\n\nifrs-full:IssuedCapitalMember\n\n2024-07-15\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementOneMember\n\n2024-09-24\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementOneMember\n\n2025-10-29\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementOneMember\n\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementTwoMember\n\n2024-10-28\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementTwoMember\n\n2025-10-29\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementTwoMember\n\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementThreeMember\n\n2025-01-16\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementThreeMember\n\n2025-10-29\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementThreeMember\n\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementFourMember\n\n2025-10-29\n2025-10-29\n\n0001849296\n\nOKYO:UnsecuredLoanAgreementFourMember\n\n2025-10-29\n\n0001849296\n\nOKYO:JohnBrancaccioMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:BernardDenoyerMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:WillySimonMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:GabrieleCerroneMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nifrs-full:NotLaterThanOneYearMember\n\n2026-03-31\n\n0001849296\n\nifrs-full:NotLaterThanOneYearMember\n\n2025-03-31\n\n0001849296\n\nOKYO:PKFLittlejohnLLPMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:PKFLittlejohnLLPMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:PKFLittlejohnLLPMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:MazarsLLPMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:MazarsLLPMember\n\n2024-04-01\n2025-03-31\n\n0001849296\n\nOKYO:MazarsLLPMember\n\n2023-04-01\n2024-03-31\n\n0001849296\n\nOKYO:BritishPoundSterlingMember\n\n2026-03-31\n\n0001849296\n\nOKYO:BritishPoundSterlingMember\n\n2025-03-31\n\n0001849296\n\nOKYO:EuropeanMember\n\n2026-03-31\n\n0001849296\n\nOKYO:EuropeanMember\n\n2025-03-31\n\n0001849296\n\nOKYO:UnitedStatesDollarMember\n\n2026-03-31\n\n0001849296\n\nOKYO:UnitedStatesDollarMember\n\n2025-03-31\n\n0001849296\n\n2025-10-29\n\n0001849296\n\n2025-10-29\n2025-10-29\n\n0001849296\n\nOKYO:PhaseIHumanClinicalTrialMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:PhaseIIHumanClinicalTrialMember\n\n2025-04-01\n2026-03-31\n\n0001849296\n\nOKYO:PhaseIIIHumanClinicalTrialMember\n\n2025-04-01\n2026-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\niso4217:GBP\n\nOKYO:Integer\n\niso4217:GBP\n\nxbrli:shares\n\n \n\n****\n\n \n\n****\n\n** **\n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n20-F**\n\n \n\n☐**REGISTRATION\nSTATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**OR**\n\n \n\n☒\n**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe fiscal year ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from to**\n\n \n\n**OR**\n\n \n\n☐\n**SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nCommission\nfile number: 001-41386\n\n \n\n**OKYO\nPharma Limited**\n\n(Exact\nname of Registrant as specified in its charter and translation of Registrant’s name into English)\n\n \n\n**Guernsey**\n\n(Jurisdiction\nof incorporation or organization)\n\n \n\n**OKYO\nPharma Limited**\n\n**Martello\nCourt**\n\n**Admiral\nPark**\n\n**St.\nPeter Port**\n\n**Guernsey\nGY1 3HB**\n\n(Address\nof principal executive offices)\n\n \n\n**OKYO\nPharma Limited**\n\n**Chief\nFinancial Officer**\n\n**107\nCheapside**\n\n**London\nEC2V 6DN**\n\n**United\nKingdom**\n\n**+44\n20 7495 2379**\n\n**E-mail:kshah@okyopharma.com**\n\n(Name,\nTelephone, E-mail and/or Facsimile number and Address of Company Contact Person)\n\n \n\nCopies\nto:\n\n \n\n**Ed\nLukins**\n\n**Orrick,\nHerrington & Sutcliffe (UK) LLP**\n\n**107\nCheapside**\n\n**London\nEC2V 6DN**\n\n**United\nKingdom**\n\n \n\nSecurities\nregistered or to be registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Name\nof each exchange on which registered**\n\nOrdinary\nShares of no par value\n \nNASDAQ\nCapital Market\n\n \n\nSecurities\nregistered or to be registered pursuant to Section 12(g) of the Act: **None**\n\n \n\nSecurities\nfor which there is a reporting obligation pursuant to Section 15(d) of the Act: **None**\n\n \n\nNumber\nof outstanding shares of each of the issuer’s classes of capital or common stock as of July 15, 2026: 52,479,527 ordinary shares.\n\n \n\nIndicate\nby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.\n\n \n\n☐\nYes ☒ No\n\n \n\nIf\nthis report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section\n13 or 15 (d) of the Securities Exchange Act of 1934.\n\n \n\n☐\nYes ☒ No\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days.\n\n \n\n☒\nYes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data\nFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding\n12 months (or for such shorter period that the registrant was required to submit and post such files).\n\n \n\n☒\nYes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting\ncompany, or an emerging growth company. See definitions of “large accelerated filer, “accelerated filer”, “smaller\nreporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):\n\n \n\nLarge\naccelerated filer ☐\nAccelerated\nfiler ☐\nNon-accelerated\nfiler ☒\nSmaller\nreporting company ☒\n\n \n \n \nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by checkmark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided\npursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n†\nThe term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards\nBoard to its Accounting Standards Codification after April 5, 2012.\n\n \n\nIndicate\nby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness\nof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered\npublic accounting firm that prepared or issued its audit report. ☐\n\n \n\nIf\nthe securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant\nincluded in the filing reflect the correction of an error to previously issued financial statements. ☐\n\n \n\nIndicate\nby check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation\nreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\n \n\nIndicate\nby check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:\n\n \n\nU.S.\nGAAP ☐\n \n\nInternational Financial Reporting Standards as issued by the\n\nInternational\nAccounting Standards Board ☒\n\n \nOther\n☐\n\n \n\nIf\n“Other” has been checked in response to the previous question, indicate by check mark which financial statement item the\nregistrant has elected to follow:\n\n \n\n☐"}